Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Equity Income (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 8 years of Equity Income data on record, last reported at -$7000.0 in Q4 2025.

  • For Q4 2025, Equity Income fell 163.64% year-over-year to -$7000.0; the TTM value through Dec 2025 reached -$8000.0, down 100.0%, while the annual FY2025 figure was -$8000.0, 100.0% down from the prior year.
  • Equity Income reached -$7000.0 in Q4 2025 per LCTX's latest filing, down from $6000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $147000.0 in Q4 2023 and bottomed at -$233000.0 in Q3 2022.
  • Average Equity Income over 4 years is -$19250.0, with a median of -$5000.0 recorded in 2024.
  • Peak YoY movement for Equity Income: soared 93.33% in 2024, then tumbled 163.64% in 2025.
  • A 4-year view of Equity Income shows it stood at -$233000.0 in 2022, then soared by 163.09% to $147000.0 in 2023, then crashed by 92.52% to $11000.0 in 2024, then plummeted by 163.64% to -$7000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Income were -$7000.0 in Q4 2025, $6000.0 in Q3 2025, and -$2000.0 in Q2 2025.